Currently, Acadia Pharmaceuticals Inc [ACAD] is trading at $24.75, up 2.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The ACAD shares have gain 2.29% over the last week, with a monthly amount drifted -0.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on May 21, 2025, when Deutsche Bank upgraded its rating to a Buy but kept the price target unchanged to $35 for it. Previously, Deutsche Bank started tracking the stock with Hold rating on February 11, 2025, and set its price target to $22. On January 03, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $20 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $20 on August 07, 2024. BMO Capital Markets started tracking with a Outperform rating for this stock on June 27, 2024, and assigned it a price target of $31. In a note dated March 12, 2024, Needham reiterated an Buy rating on this stock and revised its target price from $36 to $32.
This stock has fluctuated between a low of $13.40 and a high of $26.65 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $29.4 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $24.75 at the most recent close of the market. An investor can expect a potential return of 18.79% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
Trailing Twelve Months sales for Acadia Pharmaceuticals Inc [NASDAQ:ACAD] were 1.02B which represents 9.34% growth. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.31 and Total Capital is 0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Acadia Pharmaceuticals Inc [NASDAQ:ACAD] is 2.91. On the other hand, the Quick Ratio is 2.83, and the Cash Ratio is 0.77. Considering the valuation of this stock, the price to sales ratio is 4.10, the price to book ratio is 5.08 and price to earnings (TTM) ratio is 18.60.
Transactions by insiders
Recent insider trading involved Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, that happened on Sep 15 ’25 when 3498.0 shares were sold. Director, GAROFALO ELIZABETH A. completed a deal on Sep 02 ’25 to sell 1600.0 shares. Meanwhile, EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold 22000.0 shares on Aug 18 ’25.
